1. December 18, 2015
CURRICULUM VITAE
Jeffrey C. Fink, M.D., M.S.
Professor, Department of Medicine and Epidemiology (secondary)
Chief, Division of General Internal Medicine
University of Maryland School of Medicine
Education
1979 - 1983 B.A. Clark University, Worcester, Massachusetts
1983 - 1987 M.D. Case Western University School of Medicine, Cleveland, Ohio
1994 - 1996 M.S. Master of Science Program, Department of Epidemiology
School of Public Health and Community Medicine
University of Washington, Seattle, Washington
Post Graduate Education
1987 - 1990 Intern and Resident in Medicine
University of Washington
Seattle, Washington
1993 - 1994 Clinical Fellow, Division of Nephrology
University of Washington
Seattle, Washington
1994 - 1996 Research Fellow, Division of Nephrology
University of Washington
Seattle, Washington
Certifications
1990-2000 Diplomate, American Board of Internal Medicine
1996-2006 Diplomate, American Board of Internal Medicine, Nephrology
2000-2010 Recertified, Diplomate, American Board of Internal Medicine
2000-2014 Recertified, American Board of Internal Medicine, Nephrology
2015- Recertified, American Board of Internal Medicine, Nephrology
Medical Licensures

2. Jeffrey C. Fink, M.D., M.S.
Page 2 of 24
1987 - 1990 Washington 26537 (inactive)
1987-1988 Ohio 35055668 (inactive)
1990 - 1992 Massachusetts (inactive)
1992 - 1993 California A-50256 (inactive)
1993 - 1996 Washington 26537 (inactive)
1996 - present Maryland (active)
Employment History
Academic Appointments
1990 - 1992 Assistant Professor of Medicine
Division of General Internal Medicine, Department of Medicine
Tufts University School of Medicine, Boston, MA
1992 - 1993 Assistant Professor of Medicine
Division of General Internal Medicine, Department of Medicine
University of Southern California, Los Angeles, CA
1996 -2002 Assistant Professor, Departments of Medicine and Epidemiology Division
of Nephrology
University of Maryland School of Medicine (UMSOM), Baltimore, MD
2002 - 2011 Associate Professor, Departments of Medicine and Epidemiology
(secondary)
Division of Nephrology (UMSOM)
July 2011- Professor, Departments of Medicine and Epidemiology (secondary)
Division of Nephrology (UMSOM)
Other Employment
1990 - 1992 Staff Physician
New England Medical Center, Boston, MA
1992 - 1993 Staff Physician
University of Southern California Medical Center
Los Angeles County Medical Center, Los Angeles, CA
1996 - present Staff Physician
University of Maryland Medical Center (UMMC)
Baltimore VA Medical Center, (BVMAC), Baltimore, MD

3. Jeffrey C. Fink, M.D., M.S.
Page 3 of 24
Feb 2014- Chief, Division of General Internal Medicine (UMSOM)
Professional Society Memberships
1990 - present American College of Physicians
1993 - present National Kidney Foundation
1993 - present American Society of Nephrology
1999 - 2007 American Society of Transplantation
2001 - 2007 American Heart Association
Honors and Awards
1982 Phi Beta Kappa, Clark University
1999 American Society of Nephrology, Carl W. Gottschalk Research Award
2005 Fellow, American Society of Nephrology
2011 Fellow, National Kidney Foundation
2016 Fellow, American College of Physicians
Clinical Activities
2000 - present Founder and Director, Early Renal Insufficiency (ERI) Program (2 clinics)
UMMC ERI Clinic (established 2000)
Over 800 patients seen since inception with 250 active patients per year
Pilot site for NIH National Kidney Disease Education Program
educational outreach activities
Platform for multiple clinical research activities
Showcase program for junior faculty recruitment
Duties: 0.5 day clinic; 0.25 day administrative
Baltimore VAMC ERI clinic (established 2001)
Over 1200 patients seen since inception with 530 active patients per year
Extension of Early Renal Insufficiency (ERI) program from UMMS
Platform for multiple clinical research activities
Duties: 0.5 + 0.25 day clinic; 0.25 day administrative
Administrative Services
Institutional Service (University of Maryland)
2000-2002 School of Medicine Dean’s Council
2001 Faculty Practice Office, Space Committee
2005-2007 Faculty Senate
2006-present UMSOM Institutional Review Board
2006-present UMSOM GCRC Advisory Committee
2008 Director, Baltimore VA Pre-transplant services

4. Jeffrey C. Fink, M.D., M.S.
Page 4 of 24
Local and National Service
1992 Expert Witness for United States Attorney, U.S. vs. Smushkevich, et al.
1997 - 2007 National Kidney Foundation of Maryland, Medical Advisory Board
1997 - 2006 Mid-Atlantic Renal Coalition, Medical Research Board
2001 - 2004 National Kidney Foundation of Maryland, Grant Review Committee
2001 - 2002 American Society of Nephrology, Clinical Science Committee
2001 - 2002 Editorial Board, American Journal of Kidney Disease
2002 National Kidney Foundation, Career Development Grant Review
Committee
2002 - 2010 Maryland Kidney Commission, (Chair 2002-2006; 2009 - 2010)
2002 - present NIDDK Chronic Renal Insufficiency Cohort (CRIC) Steering Committee
2003 - 2004 National Kidney Disease Education Program, Baltimore Co-Chairman
2004 - 2007 Editorial Board, Journal of the American Society of Nephrology
2004 - 2009 American Society of Nephrology, Chronic Kidney Disease Advisory
Committee
2006 - present Paul Teschan Research Fund Grant Reviewer
2006 - present NIDDK Data Safety and Monitoring Board (DSMB) for Clinical Trial of
Oral versus IV Iron in CKD Patients (PI Agarwal)
2008 NIH Special Emphasis Scientific Review Group
Ancillary Studies in the Natural History of Acute Kidney Injury
ZDK1 GRB-7 (M1)
2008 NIH Scientific Review Group
Pilot and Feasibility Grants in Kidney
Disease (PAR 06-113) ZRG1 RUS-F S (7/24/08)
2009 NIH Scientific Review Group
Nephrology and Urology Clinical and Small Business Grants 2009/05
ZRG1 DKUS-G (51) S (4/6-4/7)
2009 - 2011 Associate Editor, American Journal of Kidney Disease
2009 - present Editorial Board, Clinical Nephrology
2009 - 2010 American Society of Nephrology, Clinical Science Committee
2009 NIH Scientific Review Group, Chair
Pilot and Feasibility Grants in Kidney
and Urological Disease
ZRG1 DKUS-G (51) (10/08-10/13)
2009 NIH Scientific Review Group
CKD Biomarkers Ancillary Studies
ZDK1 GRB-6 (J1) 1 (11/16)
2009 NIH Scientific Review Group
NIDDK R01 Ancillary Studies
ZDK1 GRB-G (J4) 1 (11/20/09)
2009 - present NIDDK CRIC Study Publication Executive Committee (Co-chair)
2010 - present Associate Editor, Clinical Journal of the American Society of Nephrology

5. Jeffrey C. Fink, M.D., M.S.
Page 5 of 24
2010 ZDK1 GRB-7 (J3) (12/07/10)
NIH Scientific Review Group
Pediatric Ancillary Study to ASSESS-AKI
2011- 2012 American Society of Nephrology, Quality and Patient Safety Task Force
and Choose Wisely Initiative (ABIM)
2010- 2014 American Society of Nephrology, CKD Advisory Group
2012 ZRG1 DKUS-L (11) B
NIH Scientific Review Group
Review of Nephrology Small Business Applications
2012 ZRG1 PSE-N (57) R (4/19/12)
NIH Scientific Review Group
FIRCA and GRIP in Behavioral/Social Sciences
2012 ZRG1 DKUS-L 80 S (6/25/12-6/26/12)
NIH Scientific Review Group, Study Section Chair
Clinical Nephrology/Urology Special Emphasis Panel
2012 RZRG1 DKUS-L (80) S
Ancillary Studies to Major Ongoing Clinical Research
Studies to Advance Scientific Interest within NIDDK (R01) (7/11/12)
NIH Scientific Review Group, Study Section Chair
2013 PAR-DK 12-509 Limited Competition Acute Kidney Injury Study Section
(U01) , ZDK1 GRB-C (M1), NIH Scientific Review Group
Teaching Service
Residents/Fellows
1996 - 1998 Attending on UMMC Medical Service, 1 month per year
Conducted daily teaching rounds and weekly lectures, 2 hours per day
4 medical residents per month
2007 - present Attending on Medical Service, BVAMC 1 month per year
Conducted daily teaching rounds and weekly lectures
4 medical residents per month
2007 - 2009 Attending on Transplant Service, UMMC 1 month per year
Conduct daily teaching rounds 2 surgical residents in conjunction with
surgery attending, 1 hour per day
1996 – 1998 Renal Journal Club
Lead 3 to 4 one hour conferences per year; attended by 3-4 nephrology
fellows

6. Jeffrey C. Fink, M.D., M.S.
Page 6 of 24
Students
1996 – 1998 Attending on UMMC Medical Service, 1 month per year
Conducted daily teaching rounds and weekly lectures, 2 hours per day
2 third yr medical students per month
2007 - present Attending on Medical Service, BVAMC, 1 month per year
Conducted daily teaching rounds and weekly lectures, 2 hours per day
2 third yr medical students, and 1 fourth yr medical student per month
1997 - 2000 Small Group Leader, Renal Pathophysiology and Therapeutics
Lead 3 small group sessions per year, 2 hours per session
Attended by 5-10 second year medical students
1997 - 2000 Small Group Leader, Cardiovascular Pharmacology
Lead 2 small group sessions per year, 2 hours per session
Attended by 5-10 first year medical students
2000 Department of Epidemiology Clinical Epidemiology Seminar
1 hour lecture/25 medical students and fellows (July 17)
2000 - present Early Renal Insufficiency Teaching Conference, 1 hour per month
Conduct monthly conference attended by 1 nurse practitioner, nephrology
fellows, 2 additional staff physicians and staff (1 RN, 1dietician, 1 SW, 1
administrative person
2001 - 2003 Department of Medicine Continuing Medical Education Program
1 hour/50-75 guest physicians (June 18)
2005 Ambulatory care conference, University of Maryland
1 hour/20 medical residents (July 29)
2006 Small group March 31st
Acid Base, 2 hours/20 medical students
2008 Small groups April 1 & 2nd
8-10AM Renal Pathophysiology
2 hours per session/20 medical students per session
2009 Renal Pathophysiology and Therapeutics
Small groups March 25, 26, 27, April 1 & 3
2 hours per session/20 medical students per session
2010 Renal Pathophysiology and Therapeutics
Small group April 8, 2 hours/20 medical students

7. Jeffrey C. Fink, M.D., M.S.
Page 7 of 24
2012 Renal Pathophysiology and Therapeutics
Hypertension (SG-08), Nov 30, 2 hours/20 medical student
2013 Renal Pathophysiology and Therapeutics
Small groups March 27, 28, 29, 2 hours each/20 medical students
Research Mentoring
Students
1996 Kennedy Gabregiorgish, 3rd
year medical student, 20 hours mentoring
1997 Mark Flasar, 3rd
year medical student, 20 hours mentoring
2006 Yonaton Spotler, 3rd
year medical student, 20 hours mentoring
(see publication)
2008 Lisa Einhorn, 1st
year medical student, 20 hours mentoring
(see publication)
2008 Maureen Moen, 1st
year medical student, 20 hours mentoring American
Society of Nephrology Student Research Fellow
(see publication)
2009 Erica Chapin, 1st
year medical student, 20 hours mentoring
(see publication)
2010 Krupa Patel, 1st
year medical student, 20 hours mentoring
American Society of Nephrology Student Research Fellow
(see publication)
2011 Nizar Dowla, 1st
year medical student, 20 hours mentoring
American Society of Nephrology Student Research Fellow
2011 Iris Hartley, 1st
year medical student, 20 hours mentoring
2013 Julianna Wu, 1st
year medical student, 20 hours mentoring
Residents
1998 Rachel (Burdick) Fissel, 2nd
year resident, 20 hrs mentoring (see
publication)
1999 Manoj Reddy, 2nd
year resident, 20 hrs mentoring (see publication)
2000 Daniel Weiner, 3rd
year resident, 20 hours mentoring

8. Jeffrey C. Fink, M.D., M.S.
Page 8 of 24
Fellows
2004 - 2007 Charlotte Jones-Burton, MD, MS Renal Fellow, (see publications)
80 hours mentoring, NRSA Fellow Award Recipient
Faculty
2005 - 2007 Stephen Seliger MD, MS, Assistant Professor (see publications)
80 hours direct mentoring
K-23 award recipient
2007 - 2009 Afshin Parsa, MD, MPH, Assistant Professor
60 hours direct mentoring
K-12 Institutional award recipient
2010 - Clarissa Diamantidis, MD, MS, Assistant Professor (see publications)
60 hours direct mentoring (to date)
Mentoring Committee (K-award recipient, transferred to Duke University)
2015- Shoshana Weiner MD, MPH
Grant Support
Active Grants
10/01/01 – 04/30/18 Site Investigator, 20% effort (PI: Appel)
NIDDK UO1, DK61022
Chronic Renal Insufficiency Cohort Study
Annual direct cost (to site): $224,961
Total direct cost (to site): $1,639,923
CRIC is a multi-center cohort study examining the natural history of
persons with chronic kidney disease (n = 3939). Dr Fink is the site PI
overseeing study activities on 256 local enrollees and serving as a member
of the study steering committee.
01/1/16-12/31/20 Co-investigator, 10% effort, (PI, Rajagopalan)
NHLBI R01HL127422
Mineralocorticoid receptor antagonism clinical evaluation in
atherosclerosis (MIRACULOUS)
Annual Direct cost: $477,818
Total direct cost: $2,400,000
MIRACULOUS is a randomized trial evaluating the effect of eplerenone
on progression of atherosclerosis in chronic kidney disease patients. Dr

9. Jeffrey C. Fink, M.D., M.S.
Page 9 of 24
Fink will serve as a the clinical investigator overseeing recruitment and
review of clinical parameters during trial.
07/01/10 – 06/30/16 Principal Investigator, 20% effort (Fink)
(NCE) NIDDK 1R01 DK084017 (scored at 2nd
percentile)
“Does under-recognition of kidney disease affect patient safety?”
Annual Direct Costs: $340,521
Total Direct Costs: $1,872,962
This grant funds the Safe Kidney Care project which will prospectively
evaluate the impact of a Medical ID alert bracelet on chronic kidney
disease recognition and assess to what extent this improves the incidence
of disease-specific safety events. Will also enroll a parallel cohort
tracked for the baseline rate of safety events in the target population.
9/20/11 – 8/31/16 Principal Investigator, 20% effort (Fink)
(NCE) NIDDK 1R01DK090008-01 (scored at 5th
percentile)
Do safety events account for adverse outcomes in CKD?
Annual Direct Costs: $343,731
Total Direct Costs: $1,189,292
This grant is an epidemiological analysis of data from the NIDDK-funded
CRIC study (see NIDDK UO1, DK61022) to identify the frequency of an
array of adverse safety events that are pertinent to kidney disease and to
determine whether these events account for some portion of poor
outcomes in this disease.
9/1/13 – 8/30/16 Principal Investigator, 20% effort (Fink)
(NCE) NIDDK 1R21 DK096204
Patient safety monitoring in kidney disease with an eDiary
Annual Direct Costs: $150,000
Total Direct Costs: $275,000
This grant proposes to evaluate an interactive voice response system to
record patient-experienced safety events among pre-dialysis CKD and
ESRD patients outside the clinic and dialysis unit.
8/1/14-7/30/16 Principal Investigator, 20% effort (Fink)
NIDDK 1R34DK102177-01
Care Coordination/Telehealth to address patient safety in CKD
Annual Direct Costs: $225,000
Total Direct Costs: $450,000
This study will examine the efficacy of a health kiosk designed to record
adverse safety events in reducing poor outcomes in CKD

10. Jeffrey C. Fink, M.D., M.S.
Page 10 of 24
Completed Grants
Extramural grants
07/97– 06/98 Principal Investigator, 2.5% effort
“Protein Catabolic Rate in the United States”
National Kidney Foundation, Maryland Chapter
Total award $4000
Total direct cost $4000
07/98 – 06/99 Principal Investigator, 2.5% effort
“How Variable is Achieved Dialysis Adequacy of ESRD Patients”
National Kidney Foundation, Maryland Chapter
Total award $3250
Total direct cost $3250
07/99 – 06/00 Principal Investigator, 10% effort
“Chronic Allograft Nephrology: A Single Center Study of its Predictors
and Outcomes.”
Hoffman-LaRoche Pharmaceuticals
Total award $41,300
Total direct cost $34,417
07/99 – 06/01 Principal Investigator, 20% effort
“Role of State and Center Effects in Dialysis Adequacy.”
American Society of Nephrology- Carl W. Gottschalk Research Award
Total Award $150,000
Total direct cost $136,364
09/04 – 07/07 Principal Investigator, 20% effort
“Center Effects Influence on Anemia and mortality”
NIH/NIDDK 1 R21 DK064126-01A1
Total award $200,000
Direct cost $148,000
09/03 – 08/07 Director, Kidney Disease Research Core, 10% effort
Project EXPORT- Comprehensive Centers in Health Disparities
NIH/NCMHD 1P60 MD000532-01 (Wilson)
Total award: $400,000, Direct cost $ 400,000
05/05 – 04/10 Site Investigator, 2% effort
Pulse wave velocity in chronic kidney disease
NIDDK R01 DK067390 (Townsend)

11. Jeffrey C. Fink, M.D., M.S.
Page 11 of 24
Annual direct cost (to site): $9000
Total direct cost (to site): $45,000
07/06 – 06//10 Principal Investigator, 5% effort
Quality of anemia management and its outcome in the VA
Amgen (administered through BREF)
Annual Direct Costs: $100,000
Total Direct Costs: $198,000
08/07 – 07/10 Principal Investigator, 20% effort
Effect of practice guidelines on care of chronic kidney disease in the VHA
NIDDK 1R21DK075675-01A1
Total award $250,000
Direct cost $172,000
03/06 – 02/11 Site Investigator, 2% effort (PI: Hsu)
CRIC-Plus Study of advanced chronic renal insufficiency
NIDDK R01 DK070939
Annual direct cost (to site): $27000
Total direct cost (to site): $125,000
02/07 – 06/11 Principal Investigator, 5% effort
“Changes in myocardial metabolism with anemia management in CKD”
Amgen
Annual Direct Costs: $127,000
Total Direct Costs: $244,500
9/09 – 8/11 Site Investigator, 1% effort (PI: Grunwald)
R-CRIC Retinopathy in chronic renal insufficiency
NIDDK R01 DK074151
Annual direct cost (to site): $43313
Total direct cost (to site): $43313
Extramural contracts
07/01/01 – 06/30/06 Co-principal Investigator, 10% effort
Principal Investigator: Dr Matthew Weir
Registry of Simulect Treated Living Transplant Recipients
Novartis Pharmaceuticals
Total award-$216,000
Total direct cost $180,000

12. Jeffrey C. Fink, M.D., M.S.
Page 12 of 24
Intramural grants
07/01/98 – 06/30/99 Principal Investigator, 5% effort
“Disparity between Maryland and Virginia in Referral of ESRD Patients
for Dialysis.”
University of Maryland School of Medicine-Pangborn Award
Total award: $15000
Total direct: cost $15000
07/01/99 – 06/30/00 Principal Investigator, 5% effort
“The Relationship Between Creatinine and Mortality in ESRD Patients”
UMB School of Medicine-Pangborn Award
Total award: $15000
Total direct cost: $15000
05/01/03 – 06/30/08 Principal Investigator, 10% effort
Relationship Between Tobacco and Kidney Disease
Maryland Cigarette Restitution Fund
Total award: $235,000
Direct cost: $235,000
09/01/05 – 07/30/09 Research Mentor (to Dr Afshin Parsa), 2.5% effort
NIH/NCRR 5K12 RR023250 (Shuldiner)
Clinical Research Career Development Award
Direct cost (to mentor): $5000 annually
Publications
Peer-reviewed journal articles
1. Politser PE, Powell SH, Fink JC. New method for reporting the source of abnormal
activities of LDH in serum. Clinical Chemistry 1986; 32:1517-1524.
2. Fink JC, Schmid CH, Selker HP. A Decision Aid for Referring Patients with Systolic
Murmurs for Echocardiography. J Gen Int Med 1994; 9:479-484.
3. Fink JC, Cooper MA, Burkhart KM, McDonald GB, Zager RA. Marked Enzymuria
Following Bone Marrow Transplantation: a Correlate of Veno-occlusive Disease Induced
Hepatorenal Syndrome. J Am Soc Nephrol 1995; 6:1655-1660.
4. Fink JC, Cooper MA, Zager RA: Hemodialysis induces tubular injury in patients with acute
renal failure. Renal Failure, 1996; 18: 947-949.
5. Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, Hoehn-Saric E, Klassen
DK, Cangro CB, Johnson LB, Kuo PC, Lim JY, Bartlett ST. A novel approach to the
treatment of chronic allograft nephropathy. Transplantation, 1997; 64:1706-1710.
6. Roghmann MC, Fink JC, Polish L, Maker T, Brewrink J, Morris JG, Light PD. Colonization
with Vancomycin-resistant enterococci in chronic hemodialysis patients. Am J Kidney
Dis, 1998; 32:254-257.

13. Jeffrey C. Fink, M.D., M.S.
Page 13 of 24
7. Fink JC, Leisenring WM, Sherrard DJ, Weiss NS. Risk factors for avascular necrosis
following bone marrow transplantation: a case control study. Bone 1998; 22:67-71.
8. Fink JC, Schwartz SM, Bennedetti TJ, Stehman-Breen CO. Increased Risk of Adverse
Maternal and Fetal Outcomes Among Women With Renal Disease. Pediatric and Perinatal
Epidemiology. 1998; 12:277-287.
9. Schweitzer EJ, Yoon S, Fink J, Wiland A, Anderson L, Kuo PC, Lim JW, Johnson LB,
Farney AC, Weir MR, Bartlett ST. Mycophenolate Mofetil reduces the risk of acute
rejection less in African-American than in Caucasian kidney recipients. Transplantation
1998; 65:242-248.
10. Drachenberg CB, Papadimitriou JC, Klassen DK, Weir MR, Cangro CB, Fink JC, Bartlett
ST. Chronic pancreas allograft rejection: morphologic evidence of progression in needle
biopsies and proposal of a grading scheme. Transplantation Proceedings, 1999; 31:614.
11. Fink JC, Armistead N, Turner M, Gardner J, Light P. Hemodialysis adequacy in Network 5:
disparity between states and the role of center effects. Am J Kidney Dis, 1999; 33:97-103.
12. Fink JC, Burdick RA, Kurth S, Armistead N, Turner M, Shickle L, Light PD. The
significance of serum creatinine values in incident end stage renal disease patients. Am J
Kidney Dis 1999; 34: 694-701.
13. Drachenberg CB, Beskow CO, Cangro CB, Bourquin PM, Simsir A, Fink J, Weir MR,
Klassen DK, et al. Human polyoma virus in renal allograft biopsies: morphological
findings and correlation with urine cytology. Human Pathology 1999; 30, 970-977.
14. Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, Cangro CB,
Blahut S, Papadimitriou. Islet cell damage associated with tacrolimus and cyclosporine:
morphological features in pancreas allograft biopsies and clinical correlation.
Transplantation 1999; 68:396-402.
15. Nogueira JM, Cangro CB, Fink JC, Klassen DK, Gardner J, Schweitzer E, Wiland A,
Flowers J, Jacobs S, Cho E, Philosophe B, Bartlett ST, Weir MR. A comparison of
recipient renal outcomes with laparoscopic versus open live donor nephrectomy.
Transplantation 1999; 67:722-728.
16. Papadimitriou JC, Drachenberg CB, Wiland A, Klassen DK, Fink J, Weir MR, Cangro C, EJ
Schweitzer, Bartlett ST. Histologic grading of acute allograft rejection in pancreas needle
biopsy. Transplantation, 1999; 66: 1741-1745.
17. Passalacqua JA, Wiland AM, Fink JC, Bartlett ST, Evans DA, Keay S. Increased incidence
of postoperative infections associated with peritoneal dialysis in renal transplant recipients.
Transplantation 1999; 68:535-540.
18. Weir MR and Fink JC. Post-transplant Diabetes Mellitus: risks versus benefits with current
immunosuppressive medications. Am J Kidney Dis; 1999 34:1-14.
19. Weir MR, Fink JC, Hanes DS, Gardner J, Klassen DK, Cangro C, Schweitzer E, Bartlett ST.
Chronic allograft nephropathy: effect of cyclosporine reduction and addition of
mycophenolate mofetil on progression of renal disease. Transplant Proceedings, 1999; 31:
1296-1287.
20. Fink JC, Gardner JF, Armistead NC, Turner MS, Light PD. Within center correlation in
dialysis adequacy. J Clin Epidemiology 2000; 53: 79-85.
21. Jacobs SC, Cho E, Dunkin, BJ, Flowers JL, Schweitzer E, Cangro C, Fink J, Farney A,
Philosophe B, Jarrell B, Bartlett ST. Laparoscopic live donor nephrectomy: the University
of Maryland 3-YEAR experience. J Urol 2000; 164:1494-1499.
22. Stehman-Breen CO, Miller L, Fink J, Schwartz SM. Preeclampsia and premature labor

14. Jeffrey C. Fink, M.D., M.S.
Page 14 of 24
among women with hematuria. Paediatric and Perinatal Epidemiology 2000; 14:136-140.
23. Fink JC, Blahut SA, Briglia AE, Gardner JF, Light PD. The effect of center versus patient-
specific factors on variations in dialysis adequacy. J Am Soc Nephrol 2001; 12: 164-169.
24. Fink JC, Blahut SA, Weir MR, Sawyer R, Henrich WL, Hise MK. The inevitability of
renal function loss in patients with hypercreatinemia. Am J Nephrol 2001; 21:386-389.
25. Fink JC, Rochussen J, Blahut SA, Reddy M, Light PD. The use of erythropoietin prior to
the initiation of dialysis and its impact on mortality in new end stage renal disease patients.
Am J Kidney Dis 2001; 37: 348-355.
26. Stern JM, Sullivan KM, Ott SM, Seidel K, Fink JC, Longton G, Sherrard DJ. Bone density
loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol
Blood Marrow Transplant 2001; 7: 257-264
27. Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique
to compare effects of diuretics and angiotensin converting enzyme inhibitors to alleviate
lower extremity edema due to dihydropyridine calcium channel antagonists. Am J
Hypertens 2001; 14: 963-968.
28. Weir MR, Ward MT, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC. The long
term impact of calcineurin inhibitor reduction or discontinuation in patients with declining
kidney function due to chronic allograft nephropathy. Kidney Int 2001; 59: 1567-1573.
29. Fink JC, Blahut SA, Weir MR. Optimal strategies for modeling the reciprocal of creatinine
versus time in renal transplant recipients and patients with native chronic kidney disease.
Am J Kidney Dis 2002; 39: 753-761.
30. Fink JC, Onuigbo MA, Blahut SA, Christenson RH, Mann D, Bartlett ST, Weir MR. Pre-
transplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal
transplant recipients: a pilot case-control study. Am J Kidney Disease 2002; 39:1096-
1101.
31. Fink JC, Zhan M, Blahut SA, Soucie M, McClellan WM. Measuring the efficacy of a
quality improvement program in dialysis adequacy with changes in center effects. J Am
Soc Nephrol 2002; 39 2338-2344.
32. Ramos E, Drachenberg CB, Papadimitriou JC, Hamze O, Fink JC, Klassen DK,
Drachenberg RC, Wiland A, Wali R, Cangro CB, Schweitzer E, Bartlett ST, Weir MR.
Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc
Nephrol 2002; 13: 214-2151.
33. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS,
Eddington ND Weir MR, Henrich WL. Characterization of hepatic cytochrome P4503A in
patients with end-stage renal disease. Clin Pharm Therap 2003; 73: 427-434.
34. Feldman, HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, et al., The
Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc
Nephrol; 2003; 14: S148-S153.
35. Gehr T, Bender F, Fink J, Light P, Elliott K, Shield C, Turner M, Mays C, Parrish J,
Armistead N. Improving adequacy of peritoneal dialysis in ESRD Network 5. Adv Perit
Dial 2003; 19: 86-92.
36. Ramos E, Drachenberg CB, Portocarrero M, Wali R, Klassen DK, Fink JC, Farney A,
Hirsch H, Papadimitriou JC, Cangro CB, Weir MR, Bartlett ST, BK virus nephropathy
diagnosis and treatment: experience at the University of Maryland Renal Transplant
Program. Clin Transpl 2003: 143-153.
37. Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC, Perencevich EN. The

15. Jeffrey C. Fink, M.D., M.S.
Page 15 of 24
use and interpretation of quasi-experimental designs in infectious diseases. Clin Infect Dis
2004; 38:1586-91.
38. Provenzano R, Garcia-Mayol L, Suchinda P, Von Hartitzsch B, Woollen SB, Zabaneh R,
Fink JC. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin
Nephrol 2004; 61: 392-405.
39. Weir MR, Blahut SA, Drachenberg C, Young C, Papademitriou J, Klassen DK, Cangro CB,
Bartlett ST, Fink JC. Late Calcineurin Inhibitor Withdrawal As A Strategy to Prevent
Graft Loss in Patients with Suboptimal Kidney Transplant Function. Am J Nephrol 2004;
24: 379-386.
40. Wiland AM, Fink JC, Weir MR, Philosophe B, Blahut S, Weir MR Jr, Copenhaver B,
Bartlett ST. Should Living Unrelated Renal Transplants Receive Antibody Induction?
Results of a Clinical Experience Trial. Transplantation 2004; 77: 422-425.
41. Ble A, Fink JC, Woodman RC, Klausner MA, Windham BG, Guralnik JM, Ferrucci L.
Renal function, erythropoietin and anemia of older persons: the InChianti Study. Arch
Intern Med 2005; 165: 2222-2227.
42. deFilippi C, Fink JC, Nass CM, Loukonen D; Chen C, Christenson R; Pro-B-type natriuretic
peptide predicts coronary disease and left ventricular hypertrophy in asymptomatic chronic
kidney disease patients not requiring renal replacement therapy. Am J Kidney Dis 2005:
46: 35-44.
43. Jones-Burton C, Brown J, Miranda M, Passmore SR, Royak Schaler R, Fink JC “Awareness
of the Association Between Smoking and Kidney Disease among African-Americans”
JAAMP 2005;16:15-20
44. Jones –Burton C, Seliger SL, Brown J, Stackiewicz L, Doren Hsu V, Fink JC Racial
variations in erythropoietic response to epoetin alfa in chronic kidney disease and the
impact of smoking. Nephrol Dial Transplant 2005; 20: 2739-2745.
45. Lu WX, Jones-Burton J, Zhan M, Salzber DJ, Moore Jr J, Fink JC. Survival Benefit of
Recombinant Human Erythropoietin Administration prior to Onset of End-Stage Renal
Disease: Variations across Surrogates for Quality of Care and Time Nephron Clin Pract
2005; 101: c79-c86.
46. McGregor JC, Kim PW, Perencevich EN, Bradham DD, Furuno JP, Kaye KS, Fink JC,
Langenberg P, Roghmann MC, Harris AD. The Utility of the Chronic Disease Score and
Charlson Comorbidity Index as Comorbidity Measures for use in Epidemiologic Studies of
Antibiotic-Resistant Organisms. Am J Epidemiol. 2005; 161: 483-493.
47. Mishra SI, Jones-Burton C, Fink JC, Brown J, Bakris GL, Weir MR. Does dietary salt
increase the risk of progression of kidney disease? Curr Hypertens Rep 2005; 7: 385-391.
48. Wali RK, Wang GS, Gottlieb SS, Bellumkonda L, Hansalia R, Ramos E, Drachenberg C,
Papadimitriou J, Brisco MA, Blahut S, Fink JC, Fisher ML, Bartlett ST, Weir MR. Effect
of kidney transplantation on left ventricular systolic dysfunction and congestive heart
failure in patients with end-stage renal disease. J Am Coll Card; 2005 45: 1051-1060.
49. Weir MR and Fink JC. Salt Intake and Progression of Chronic Kidney Disease: An
overlooked modifiable exposure? A Commentary. Am J Kidney Dis 2005; 45: 176-188.
50. Jones-Burton C, Mishra SI, Fink JC, Brown J, Gossa W, Bakris GL, Weir MR “An In-depth
Review of the Evidence Linking Dietary Salt Intake and Progression of Chronic Kidney
Disease” Am J Nephrol; 2006 Jun 9;26(3):268-275.
51. Khan IA, Fink J, Nass C, Chen H, Christenson R, deFilippi CR. N-terminal pro-B-type
natriuretic Peptide and B-type natriuretic Peptide for identifying coronary artery disease

16. Jeffrey C. Fink, M.D., M.S.
Page 16 of 24
and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J
Cardiol 2006; 97: 1530-1534.
52. McGregor JC, Perencevich EN, Furono JP, Langenberg P, Flannery K, Zhu J, Fink JC,
Bradham DD, Harris AD. Comorbidity risk-adjustment measures were developed and
validated for studies of antibiotic-resistant infections. J Clin Epidemiol 2006; 59:1266-73.
53. Fink JC, Hsu VD, Zhan M, Walker LD, Mullins CD, Jones-Burton C, Langenberg P, Seliger
SL. Center effects in anemia management of dialysis patients. J Am Soc Nephrol 2007; 18:
646-653.
54. Jones-Burton C, Seliger SL, Scherer R, Mishra S, Brown J, Weir M, Fink JC. Cigarette
smoking and incident chronic kidney disease: a systematic review. Am J Neprhol 2007;
27: 342-35.
55. Jones-Burton C, Vessal G, Brown J, Dowling TC, Fink JC. Urinary Cotinine as an Objective
Measure of Cigarette Smoking in Chronic Kidney Disease. Nephrol Dial Transplant 2007;
22:1950-4.
56. Spolter YS, Seliger SL, Zhan M, Hsu VD, Walker LD, Fink JC. The relationship between
dialysis performance measures: adequacy and anemia management. Am J Kidney Dis
2007; 50: 774-781.
57. Vessal G, Wiland AM, Philosophe B, Fink JC, Weir MR, Klassen DK. Early steroid
withdrawal in solitary pancreas transplantation results in equivalent graft and patient
survival compared with maintenance steroid therapy. Clin Transplant. 2007; 21:491-7.
58. Seliger SL, Katzel LI, Fink JC, Weir MR, Waldstein SR. Renal function and cardiovascular
response to mental stress. Am J Nephrol. 2008; 28:304-10.
59. Seliger SL, Zhan M, Hsu VD, Walker L, Fink JC. Chronic Kidney Disease Adversely
Influences Patient Safety. J Am Soc Nephrol. 2008 Dec;19(12):2414-9.
60. Xie D, Joffe MM, Brunelli SM, Beck G, Chertow GM, Fink JC, Greene T, Hsu CY, Kusek
JW, Landis R, Lash J, Levey AS, O'Conner A, Ojo A, Rahman M, Townsend RR, Wang H,
Feldman HI. A Comparison of Change in Measured and Estimated Glomerular Filtration
Rate in Patients with Nondiabetic Kidney Disease. Clin J Am Soc Nephrol; 2008 Sep;
3(5):1332-8.
61. Einhorn LM, Zhan M, Hsu VD, Walker L, Moen MF, Seliger SL, Weir MR, Fink JC. The
frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med
2009; 169(12):1156-1162.
62. Fink JC, Brown J, Hsu VD, Seliger SL, Walker L, Zhan M. CKD as an under-recognized
threat to patient safety. Am J Kidney Disease; 2009 53(4): 681-8.
63. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan
J, Fink JC, Fischer MJ, Gadegbeku C, Hamm LL, Kusek JW, Landis JR, Narva A,
Robinson N, Teal V, and Feldman HI on behalf of the Chronic Renal Insufficiency Cohort
Study Group. The Chronic Renal Insufficiency Cohort (CRIC) Study: Baseline
characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009; 4:
1302-11.
64. Moen MF, Zhan M, Hsu VD, Walker L, Einhorn LM, Seliger SL, Fink JC. The frequency
and significance of hypoglycemia in chronic kidney disease. Clin J Am Soc Nephrol 4:
1121-1127, 2009.
65. Semba RD, Ferrucci L, Fink JC, Sun K, Beck J, Dalal M, Guralnik JM, Fried LP. Advanced
Glycation End Products and Their Circulating Receptors and Level of Kidney Function in
Older Community-Dwelling Women. Am J Kidney Dis 2009 53: 51-8.

17. Jeffrey C. Fink, M.D., M.S.
Page 17 of 24
66. Semba RD, Fink JC, Sun K, Bandinelli S, Guralnik JM, Ferrucci L. Carboxymethyl-lysine,
an advanced glycation end product, and decline of renal function in older community-
dwelling adults. Eur J Nutr; 2009 Feb;48(1):38-44.
67. Chapin E, Zhan M, Hsu VD, Seliger SL, Walker LD, Fink JC. Adverse safety events in
chronic kidney disease: the frequency of “multiple hits”. Clin J Am Soc Nephrol; 2010 5:
87-94.
68. Fink JC, Lodge MA, Smith MF, Hinduja A, Brown J, Dinits-Pensy MY, Dilsizian V. Pre-
Clinical Myocardial Metabolic Alterations in Chronic Kidney Disease. Cardiology; 2010
116: 160-167.
69. Grunwald, JE, Alexander J, Maguire M, Whittock R, Parker C, McWilliams K, Lo JC,
Townsend R, Gadegbeku CA., Lash JP, Fink JC, Rahman M., Feldman H, Kusek J,
Ojo,A,. The CRIC Study Group. Prevalence of Ocular Fundus Pathology in Subjects with
Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study. Clin J
Am Soc Nephrol; 2010 5: 867-73.
70. Lawler EV, Gagnon DR, Fink J, Seliger S, Fonda J, Do TP, Gaziano JM, Bradbury BD.
Initiation of anaemia management in patients with chronic kidney disease not on dialysis in
the Veterans Health Administration. Nephrol Dial Transplant; 2010 25: 2237-2244.
71. Seliger SL, Fox KM, Gandra SR, Bradbury B, Hsu VD, Walker LM, Chiou CF, Fink JC.
Timing of Erythropoiesis-stimulating agent (ESA) initiation and adverse outcomes in non-
dialysis CKD: a propensity-matched observational study Clin J Am Soc Nephrol; 2010 5:
882-8.
72. Semba RD, Fink JC, Sun K, Windham BG, Ferrucci L. Serum Carboxymethyl-Lysine, a
Dominant Advanced Glycation End Product, Is Associated With Chronic Kidney Disease:
The Baltimore Longitudinal Study of Aging. J Ren Nutr; 2010 20: 74-81.
73. Seliger SL, Zhang A, Weir MR, Walker L, Hsu VD, Parsa A, Diamantidis C, Fink JC.
Erythropoiesis-stimulating agents and stroke in chronic kidney disease: a national case-
control study. Kidney Int 2011 80(3):288-94.
74. Dalal M, Semba RD, Sun K, Crasto C, Varadhan R, Bandinelli S, Fink JC, Guralnik JM,
Ferrucci L. Endogenous Secretory Receptor for Advanced Glycation End Products and
Chronic Kidney Disease in the Elderly Population. Am J Nephrol 2011 33:313-318.
75. Kop WJ, Seliger SL, Fink JC, Katz R, Odden MC, Fried LF, Rifkin DE, Sarnak MJ,
Gottdiener JS. Longitudinal Association of Depressive Symptoms with Rapid Kidney
Function Decline and Adverse Clinical Renal Disease Outcomes. Clin J Am Soc Nephrol
2011; 6:834-44.
76. Townsend RR, AndersonAH, ChenJ, Gadebegku CA, Feldman HI, Fink JC, et al. for the
CRIC Study Investigators Metabolic Syndrome, Components, and Cardiovascular Disease
Prevalence in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency
Cohort (CRIC) Study. Am J Nephrol 2011;33:477-48
77. Weir MR, Townsend RR, Fink JC, Teal V, Anderson C, Appel L, Chen J, He J, Litbarg
N, Ojo A, Rahman M, Rosen L, Sozio SM, Steigerwalt S, Strauss L, Joffe MM.
Hemodynamic Correlates of Proteinuria in Chronic Kidney Disease. Clin J Am Soc
Nephrol, 2011; 2403-10
78. Semba RD, Fink JC, Sun K, Cappola AR, Dalal M, Crasto C, Ferrucci L, Fried LP. Serum
fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-
dwelling women. Clin J Am Soc Nephrol. 2012;7:85-91

18. Jeffrey C. Fink, M.D., M.S.
Page 18 of 24
79. Parsa A, Brown E, Weir MR, Fink JC, Shuldiner AR, Mitchell BD, McArdle PF. Genotype-
based changes in uric acid affect blood pressure. Kidney Int. 2012 81:502-7
80. Fink JC, Joy MS, St Peter WL, Wahba IM, Finding a common language for patient safety
in chronic kidney disease Clin J Am Soc Nephrol 2012, 7:689-695.
81. Diamantidis CJ, Seliger SL, Zhan M, Walker LD, Rattinger GB, Hsu VD, Fink JC. A
varying patient safety profile between blacks and non-blacks with decreased estimated
GFR. Am J Kidney Dis, 2012 60:47-53, PMID: 22483674
82. Ellingson KD, Palekar RS, Lucero CA, Kurkjian KM, Chai SJ, Schlossberg DS, Vincenti
DM, Fink JC, Davies-Cole JO, Magri JM, Arduino MJ, Patel PR. Vascular access
hemorrhages contribute to deaths among hemodialysis patients. Kidney Int, 2012, ePub.
83. Patel K, Diamantidis C, Zhan M, Hsu VD, Walker LD, Gardner J, Weir MR, Fink JC.
Influence of Creatinine versus Glomerular Filtration Rate on Non-Steroidal Anti-
Inflammatory Drug Prescriptions in Chronic Kidney Disease. Am J Nephrol, 2012,
36(1):19-26
84. Diamantidis CJ, Zuckerman M, Fink W, Hu P, Yang S, Fink JC. Usability of a chronic kidney
disease educational Web site targeted to patients and their family members. Clin J Am Soc Nephrol,
2012, 7(10):1553-60
85. Grunwald JE, Alexander J, Ying GS, Maguire M, Daniel E, Whittock-Martin R, Parker C,
McWilliams K, Lo JC, Go A, Townsend R, Gadegbeku CA, Lash JP, Fink JC, Rahman M,
Feldman H, Kusek JW, Xie D, Jaar BG; for the CRIC Study Group. Retinopathy and Chronic
Kidney Disease in the Chronic Renal Insufficiency Cohort (CRIC) Study. Arch Ophthalmol. 2012
Sep 1;130(9):1136-1144
86. Williams AW, Dwyer A, Eddy AA, Fink JC, Jaber BL, Linas S et al, Critical and Honest
Conversations: The Evidence Behind the "Choosing Wisely" Campaign Recommendations by the
American Society of Nephrology. Clin J Am Soc Nephrol, 2012, 82(6):686-92
87. Weir MR, Townsend RR, Fink JC, Teal V, Sozio SM, Anderson CA, Appel LJ, Turban S,
Chen J, He J, Litbarg N, Ojo A, Rahman M, Rosen L, Steigerwalt S, Strauss L, Joffe MM.
Urinary Sodium Is a Potent Correlate of Proteinuria: Lessons from the Chronic Renal
Insufficiency Cohort Study. Am J Nephrol 36: 397-404, 2012
88. Diamantidis CJ, Zuckerman M, Fink W, Aggarwal S, Prakash D, Fink JC. Usability testing
and acceptance of a multi-platform IT Medication Inquiry System (MIS) in chronic kidney
disease (CKD). Am J Kidney Dis 61(4):644-6, 2013.
89. Gordon EJ, Fink JC, Fischer MJ Telenephrology: a novel approach to improve coordinated
and collaborative care for chronic kidney disease. Neph Dial Transplant 28:972-81, 2013
90. Gill KS, Muntner P, Lafayette RA, Petersen J, Fink JC, Gilbertson DT, Bradbury BD. Red
blod cell transfusion use in patients with chronic kidney disease. Neph Dial Transplant
28:1504-15, 2013.
91. Hartley IR, Ginsberg JS, Diamantidis CJ, Zhan M, Walker L, Rattinger RB, Fink JC.
Consideration of ICD-9 code-derived disease-specific safety indicators in CKD. Clin J Am
Soc Nephrol 8:2123-31 2013.
92. Diamantidis CJ, Fink W, Yang S, Zuckerman MA, Ginsberg J, Hu P, Xiao Y, Fink JC
Directed use of the Internet for health information by patients with chronic kidney disease:
results from Safe Kidney Care. J Med Internet Res 15:251-257, 2013
93. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW,
Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr, Lash JP, Freedman BI, Ojo A,
Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ;

19. Jeffrey C. Fink, M.D., M.S.
Page 19 of 24
AASK Study Investigators; CRIC Study Investigators APOL1 risk variants, race, and
progression of chronic kidney disease. N Engl J Med. 369:2183-96, 2013
94. Davis-Ajami ML, Wu J, Fink JC Differences in health services utilization and costs between
antihypertensive medication users versus nonusers in adults with diabetes and concomitant
hypertension from Medical Expenditure Panel Survey pooled years 2006 to 2009. Value
Health. 2014 Jan-Feb;17(1):51-61
95. Ginsberg JS, Zhan M, Diamantidis CJ, Woods C, Chen J, Fink JC. Patient-reported and
actionable safety events in chronic kidney disease. J Am Soc Nephrol, 2014, 25:1564-73
96. Grunwald JE, Pistilli M, Ying GS, Daniel E, Maguire MG, Xie D, Whittock-Martin R, Parker Ostroff
C, Lo JC, Townsend RR, Gadegbeku CA, Lash JP, Fink JC, Rahman M, Feldman HI, Kusek JW;
the Chronic Renal Insufficiency Cohort Study Investigators. Clin J Am Soc Nephrol 2014,
9(7):1217-24.
97. Ricardo AC, Anderson CA, Yang W, Zhang X, Fischer MJ, Dember LM, Fink JC, Frydrych A,
Jensvold NG, Lustigova E, Nessel LC, Porter AC, Rahman M, Wright Nunes JA, Daviglus ML,
Lash JP; CRIC Study Investigators. Healthy lifestyle and risk of kidney disease progression,
atherosclerotic events, and death in CKD: findings from the Chronic Renal Insufficiency Cohort
(CRIC) Study. Am J Kidney Dis. 2015 Mar;65(3):412-24
98. Wu J, Ginsberg JS, Zhan M, Diamantidis CJ, Chen J, Woods C, Fink JC. Chronic pain and
analgesic use in chronic kidney disease: implications for patient safety. Clin J Am Soc Nephrol
2015, 10(3):435-42
99. Croft LD, Harris AD, Pineles L, Langenberg P, Shardell M, Fink JC, Simoni-Wastila L, Morgan DJ;
Benefits of Universal Glove and Gown (BUGG) primary investigators; Benefits of Universal Glove
and Gown BUGG primary investigators. The Effect of Universal Glove and Gown Use on Adverse
Events in Intensive Care Unit (ICU) Patients. Clin Infect Dis. 2015 61(4):545-53.
100. Gill K, Fink JC, Gilbertson DT, Monda KL, Muntner P, Lafayette RA, Petersen J, Chertow GM,
Bradbury BD Red blood cell transfusion, hyperkalemia, and heart failure in advanced chronic
kidney disease. Pharmacoepidemiol Drug Saf. 2015 24(6):654-62
101. Gupta J, Dominic EA, Fink JC, Ojo AO, Barrows IR, Reilly MP, Townsend RR, Joffe MM, Rosas
SE, Wolman M, Patel SS, Keane MG, Feldman HI, Kusek JW, Raj DS; CRIC Study Investigators
Association between Inflammation and Cardiac Geometry in Chronic Kidney Disease: Findings
from the CRIC Study. PLoS One. 2015 Apr 24;10(4):e0124772
102. Wagner, LA, Tata A, Fink JC. Patient safety issues in chronic kidney disease. Am J Kidney Dis,
2015, 66(1):159-69
103. Diamantidis CJ, Ginsberg JS, Yoffe M, Lucas L, Prakash D, Aggarwal S, Fink W, Becker S, Fink
JC; Remote Usability Testing and Satisfaction with a Mobile Health Medication Inquiry System in
CKD. Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1364-70
104. Denker M, Boyle S, Anderson AH, Appel LJ, Chen J, Fink JC, Flack J, Go AS, Horwitz E, Hsu
CY, Kusek JW, Lash JP, Navaneethan S, Ojo AO, Rahman M, Steigerwalt SP, Townsend RR,
Feldman HI; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Chronic Renal
Insufficiency Cohort Study (CRIC): Overview and Summary of Selected Findings. Clin J Am Soc
Nephrol. 2015 Nov 6;10(11):2073-83.
105. Croft LD, Liquori M, Ladd J, Day H, Pineles L, Lamos E, Arnold R, Mehrotra P, Fink JC,
Langenberg P, Simoni-Wastila L, Perencevich E, Harris AD, Morgan DJ; The Effect of Contact
Precautions on Frequency of Hospital Adverse Events. Infect Control Hosp Epidemiol. 2015:
36:1268-74
106. Grunwald JE, Pistilli M, Ying GS, Maguire M, Daniel E, Whittock-Martin R, Parker-Ostroff C,
Mohler E, Lo JC, Townsend RR, Gadegbeku CA, Lash JP, Fink JC, Rahman M, Feldman H,
Kusek JW, Xie D; CRIC Study Investigators. Retinopathy and the Risk of Cardiovascular Disease

20. Jeffrey C. Fink, M.D., M.S.
Page 20 of 24
in Patients With Chronic Kidney Disease (from the Chronic Renal Insufficiency Cohort Study).
Am J Cardiol. 2015; 116(10):1527-33
107. Ricardo AC, Roy JA, Tao K, Alper A, Chen J, Drawz PE, Fink JC, Hsu CY, Kusek JW, Ojo A,
Schreiber M, Fischer MJ; CRIC Study Investigators. Influence of Nephrologist Care on
Management and Outcomes in Adults with Chronic Kidney Disease. J Gen Intern Med 2016
31(1):22-9
108. Fink JC, Doerfler RM, Yoffe MR, Diamantidis CJ, Blumenthal JB, Siddiqui T, Gardner JF, Snitker
S, Zhan M. Patient-Reported Safety Events in Chronic Kidney Disease Recorded With an
Interactive Voice-Inquiry Dial-Response System: Monthly Report Analysis. J Med Internet Res
2016, ePub
Non peer reviewed and invited journal articles
1. Fink JC, Tucker JC. The artificial heart. Health Matrix 1985.
2. Fink JC, Henrich WL. How important is volume excess in the etiology of hypertension in
dialysis patients. Semin Dialysis 1999 12: 303-304.
3. Fink JC, Henrich WL. The outcome of the urban renal patient: The importance of social
factors and center effects. Semin Nephrol 2001; 21: 356-361.
4. Fink JC. The effect of CKD therapies on serum potassium levels. Nat Rev Nephrol;
2010 6:633-634.
5. Weir MR, Fink JC. Safety of medical therapy in patients with chronic kidney disease and
end-stage renal disease. Curr Opin Nephrol Hypertens. 2014 May;23(3):306-13
Editorials
1. Dilsizian V, Fink JC. Deleterious effect of altered myocardial fatty acid metabolism in
kidney disease. JACC 2008; 51: 146-148.2.Fink JC. Do you need to finish school to get a
kidney transplant? Am J Kidney Disease 2008; 51: 717-718.
2. Fink JC, Chertow GM. Medication errors: one piece to the patient safety puzzle. Kidney
Int; 2009 76: 1123-1125.
3. Fink JC. Chronic Kidney Disease as a Potent Risk Modifier for Coronary Heart Disease
in Diabetes Mellitus. JACC Cardiovasc Imaging; 2010; 3: 746-748.
Book Chapters
1. Fink JC. Current outcomes of dialysis patients. Chapter 43, Principles and Practice of
Dialysis, Third Edition, ed Henrich WL; 2003 pages 662-672.
2. Fink JC. Current outcomes and quality of care of dialysis patients. Chapter 43, Principles
and Practices of Dialysis, Fourth Edition, ed. Henrich WL; 2009 683-694.
Selected abstract publications
1. Fink JC, Blahut SA, Briglia AE, Gardner JF, Light PD. The effect of center versus patient-
specific factors on variations in dialysis adequacy. J Am Soc Nephrol 2000; 11: 230A.

21. Jeffrey C. Fink, M.D., M.S.
Page 21 of 24
2. Fink JC, Blahut SA, Light PD, McClellan WM. Assessing the impact of a quality
improvement effort on dialysis adequacy by measuring changes in center effects. J Am
Soc Nephrol 2000; 11: 146A.
3. Fink JC, Blahut SA, Light PD. The use of erthyropoietin prior to the initiation of dialysis
and its impact on mortality. J Am Soc Nephrol 2000; 11: 146A.
4. Fink JC, Blahut SA, Weir MR. Geomapping to assess small area variations in
transplantation rates as an initial renal replacement therapy. Transplantation 2000; 69;
S116.
5. Fink JC, Blahut SA, Weir MR. Small area variations in erythopoietin use prior to initiation
of dialysis in Network 5. J Am Soc Nephrol 2000; 11: 145A.
6. Fink JC, Wiland AM, Philosophe B, Blahut SA, Rocchusen JR, Wali RK, Weir MR. The
effect of Prograf compared to Neoral on glycemic trends after renal transplantation.
Transplantation 2000; 69, S325.
7. Fink JC, Wiland AM, Rocchusen JR, Drachenberg CB, Papadimitriou JP. The increased
incidence of BK Polyoma virus in renal transplant recipients treated with Prograf.
Transplantation 2000; 69, S385.
8. Philosophe B, Fink JC, Wiland AM, Farney AC, Schweitzer EJ, Colonna JO, Jarrell BE,
Krishnamurthi V, Bartlett ST. Low kidney rejection rates with basiliximab induction and
delayed introduction of tacrolimus for patients with delayed graft function. Transplantation
2000; 69, S259.
9. Salmanullah M, Sawyer R, Henrich WL, Weir MR, Fink JC, Hise MK. The natural history
of an elevated creatinine in a VA population. J Am Soc Nephrol 2000; 11: 164A.
10. Weir MR, Traver M, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC. The long-
term impact of calcineurin inhibitor reduction or discontinuation in patients with declining
kidney function due to chronic allograft nephropathy. Transplantation 2000; 69, S163.
11. Wiland AM, Fink JC, Philosophe B, Farney A, Schweitzer EJ, Colonna JO, Weir MR,
Bartlett ST. Cost effective measures to administer Thymoglobulin for induction therapy in
pancreas transplant recipients. Transplantation 2000; 69; S408.
12. Wiland AM, Fink JC, Philosophe B, Farney AC, Schweitzer EJ, Colonna JO. Weir MR,
Bartlett ST. Experience with Thymoglobulin induction therapy in pancreas transplant
recipients. Transplantation 2000; 69; S408.
13. Fink JC, Blahut SA, Weir MR. Is Renal transplantation adequate treatment for the anemia
of renal disease? J Am Soc Nephol 2001; 12: 887A.
14. Oniquibo M, Blahut SA, Christenson R, Weir MR, Guitterrez M, Fink JC. Pre-transplant
C-reactive protein as a predictor of chronic allograft nephropathy: a case-control study.
Am J Transplant 2001; 1: 290A.
Major Invited Speeches
1. “Anemia of Chronic Kidney Disease”, University of Virginia Renal Rounds, 8-10 physicians
in attendance from renal division. Jan 26, 2001
2. “Benefits of Epoetin alfa in Treating Anemia of Chronic Kidney Disease”. MCP-
Hahnemann CME Program. 50 physicians in attendance including faculty and housestaff
from the institution. April 25, 2001
3. “Benefits of Epoetin alfa in Treating Anemia of Chronic Kidney Disease”. Easton Memorial
Hospital Grand Rounds. 12 physicians from the hospital in attendance. May 4, 2001

22. Jeffrey C. Fink, M.D., M.S.
Page 22 of 24
4. “Anemia of Chronic Kidney Disease”. Virginia Assoc. of Family Practice Physicians,
Annual Meeting. 100 family practice physicians in attendance. June 18, 2001
5. “Epidemiology of polyomovirus infection in transplantation”. NIH, NIAID Scientific
Advisory Conference, Bethesda, Maryland. 25 physician attendees. August 13, 2002
6. “Polyomavirus infection in renal transplantation”. University of Pennsylvania, Transplant
Grand Rounds. 15 Physicians in attendance. January 15, 2003
7. “Polyomavirus infection in renal transplantation”. Washington Hospital Center, Transplant
Grand Rounds. 20 Physicians in attendance. February 19, 2003
8. “Managing Chronic Kidney Disease”. Perry Point VA Medical Center, Medical Grand
Rounds. 20 Physicians in attendance. August 27, 2003
9. “Managing Chronic Kidney Disease”. Washington VA Medical Center, Nephrology
Rounds.15 Physicians in attendance. October 1, 2003
10. “Analgesic Nephropathy: recommendations for warning labels”. Staff members of US
Senate Government Affairs Committee. Washington DC. 10 Senate staffers present.
November 5, 2003
11. “Clinical care of Chronic Kidney Disease”. University of Maryland, Department of
Medicine CME program. 100 physicians present. June 9, 2004
12. “Clinical care of Chronic Kidney Disease”. University of Maryland Department of Family
Practice CME program. 100 physicians present. July 2, 2004
13. “Baltimore Coalition activities”. National Kidney Disease Education Program, NIH Steering
Committee. 30 physicians and attendees present. June 11, 2004
14. “Benefits of a Chronic Kidney Disease clinic”. American Society of Nephrology, Renal
Week. St Louis, Missouri. 75 physicians in attendance. October 28, 2004
15. “Chronic Kidney Disease Management in primary care”. Ohio State University Medical
Grand Rounds. 60 physicians in attendance. June 30, 2005
16. “Management of Chronic Kidney Disease”. Mercy Medical Center, Baltimore. 50
physicians in attendance. January 11, 2006
17. “Center effects in hemodialysis”. Mid-Atlantic Nephrology Young Investigators Forum.
Baltimore, MD. 25 physicians in attendance. March 15, 2006
18. “Chronic kidney disease management: Same old swan song?” National Capital Nephrology
Forum. National Naval Medical Center, Bethesda MD. 25 physicans in attendance. April
12, 2006
19. “Promoting the Partnership”. Symposium on Transplant and Dialysis Center Relationships.
Maryland Commission on Kidney Disease. UMBC Technology Center. 75 Health Care
Providers in Attendance. October 3, 2006
20. “Chronic Kidney Disease”. University of Maryland Mini-Medical School College of
Southern Maryland. 15 participants. October 21, 2006
21. “Chronic kidney disease management: Same old swan song?” Grand rounds, Uniformed
Services University of Health Sciences, Andrews Air Force Base. 50 participants. October
27, 2006
22. “Chronic kidney disease management: Same old swan song?” Renal Grand Rounds, JHU-
Bayview Medical Center. 20 participants. December 6, 2006
23. “Kidney Disease”. University of Maryland Statewide Health Network. Heritage United
Church of Christ, Baltimore, MD. 35 attendees. June 2, 2007

23. Jeffrey C. Fink, M.D., M.S.
Page 23 of 24
24. “Irreversible Renal Failure: Challenges and Considerations with Dialysis and
Transplantation” Learning Institute for Management of Chronic Kidney Disease, Boston,
Massachusetts. 40 attendees. October 24, 2007
25. “View from a CRIC (Chronic Renal Insufficiency Cohort Study) Clinical Center”. Chronic
Kidney Disease-Japanese CRIC meeting at the American Society of Nephrology
conference, San Francisco, California. 40 attendees present. November 3, 2007
26. “The Relationship between Smoking and Chronic Kidney Disease (CKD): Developing
Evidence Using Biological and Epidemiological Methods”. University of Maryland
Statewide Health Network, Baltimore, MD. 100 physicians and attendees present.
November 19, 2007
27. “Update on Chronic Kidney Disease”. University of Maryland Family Practice Grand
Rounds
28. 35 participants. December 5, 2007
29. “Chronic Kidney Disease and Patient Safety”. Renal Disease Interest Group. Welch Center,
Johns Hopkins University. 20 participants. January 23, 2008
30. “Natuiretic peptides in ESRD. American Society of Nephrology Annual Meeting,
Philadelphia, PA. 300 participants. November 6, 2008
31. “Disease specific safety indicators in CKD”. Renal Disease Interest Group. Welch Center,
Johns Hopkins University. 20 participants. May 27, 2009
32. “Walk the Line”. Challenge of Hypoglycemia in the CKD patient with Diabetes. National
Kidney Foundation. Case-based CME webcast. March 1, 2010“Chronic kidney disease as
a crucible of patient safety”. Welch Center Rounds, Johns Hopkins University. 40
participants. December 8, 2010
33. “Chronic kidney disease as a crucible of patient safety”. George Washington University,
Department of Medicine, Grand rounds. 150 participants. August 25, 2011
34. “Chronic kidney disease as a crucible of patient safety” Cleveland Clinic Glickman Urologic
and Kidney Institute, Renal Grand Rounds, 50 participants, February 27, 2012
35. “Subclinical harm from medication errors in chronic kidney disease”, Division of Applied
Pharmacology Research, Food and Drug Administration, 20 participants, March 23, 2012
(host: Rodney Rouse PhD)
36. “Cohort studies”, University of Maryland Department of Medicine Residents, May 11, 2012,
6 participants
37. Transitioning to Independence: A Professional Development Symposium for UMB Career
Development Awardees; Creating a Thriving Research Program: Lessons Learned from
Successful UMB Investigators: Panel participant, 25 participants, June 1, 2012 (host:
Wendy Sanders, Asst Dean, Career Development, University of Maryland, Batimore).
38. An Opportunity to Avoid Medication Errors in Patients with CKD? Kidney Week (American
Society of Nephrology National meeting), San Diego, CA, November 4, 2012, (moderator:
Andrew Narva, MD). 50 participants
39. Recognizing Patient Safety Risk in CKD. National Kidney Foundation (NKF) 2013 Spring
Clinical Meeting, April 3, 2013, Orlando, FL. 25 participants.
40. Patient safety in CKD. FDA/CDER Seminar Series. Food and Drug Administration,
December 11, 2013, Silver Spring, MD, 50 participants
41. Patient safety in CKD. Kidney Interagency Coordinating Committee Meeting, National
Institutes of Health, March 7, 2014, Bethesda, MD 30 participants

24. Jeffrey C. Fink, M.D., M.S.
Page 24 of 24
42. CKD and patient safety: Lessons on complex disease management, Harbor Hospital, Oct 30,
2014, 50 participants
43. Risk of hospitalization in CKD: do the same rules apply for patient safety? American
Society of Nephrology meeting, Phila, PA, Nov 13, 2014, 200 participants
44. Patient safety across the spectrum of kidney disease. Dialysis Clinic Inc, National Meeting,
Hilton Head, SC, April 22, 2016, 100 participants
45. Medication safety in CKD: Room for improvement (Panel Chair). National Kidney
Foundation, 2016 Spring Meeting, Boston MA; April 29, 2016, 150 participants